Invokana a Growing concern for Janssen

Invokana a Growing concern for Janssen

Introduction

J&J's Janssen Pharmaceuticals has more than 800 product liability cases across the nation for its anti-diabetic drug Invokana. This news is confirmed by J&J's quarterly financial filing with the Securities and Exchange Commission (SEC). The Invokana cases are consolidated as a part of an MDL before U.S. District Judge Brian Martinotti in the District of New Jersey and the trials for a small number of bellwether cases are expected to begin in September 2018. Apart from this, several federal cases are pending in the Southern District of California and the Eastern District of Missouri, as well as state court cases, are pending in California, New Jersey, and Pennsylvania. Allegations mainly involve kidney failure, heart attacks, and diabetic ketoacidosis, with a recent addition of increased risk of leg or foot amputations following a warning released by the FDA in May 2017.